𝙎𝙘𝙞𝙚𝙣𝙩𝙞𝙨𝙩𝙨 𝙂𝙧𝙤𝙬 “𝙢𝙞𝙣𝙞 𝙗𝙧𝙖𝙞𝙣𝙨” 𝙞𝙣 𝙩𝙝𝙚 𝙇𝙖𝙗-𝙁𝙞𝙣𝙙 𝙋𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙋𝙖𝙩𝙝 𝙛𝙤𝙧 𝙁𝙖𝙩𝙖𝙡 𝙉𝙚𝙪𝙧𝙤𝙡𝙤𝙜𝙞𝙘𝙖𝙡 𝘿𝙞𝙨𝙚𝙖𝙨𝙚
Cambridge researchers have developed ‘mini brains’ that allow them to study a fatal and untreatable neurological disorder causing paralysis and dementia – and for the first time have been able to grow these for almost a year.
A common form of motor neuron disease, amyotrophic lateral sclerosis, often overlaps with frontotemporal dementia (ALS/FTD) and can affect younger peo… See More.
Balancing Risk and Cutting Edge Medical Innovation — Dr. Paul Offit, MD, Director, Vaccine Education Center, Children’s Hospital of Philadelphia.
Dr. Paul A. Offit, MD, (https://www.paul-offit.com/) is an internationally recognized expert in the fields of virology and immunology, Co-Inventor of a landmark vaccine for the prevention of Rotavirus gastroenteritis, and holds multiple titles including — Director of the Vaccine Education Center at Children’s Hospital Of Philadelphia (CHOP), Maurice R. Hilleman Chair of Vaccinology and Professor of Pediatrics, Perelmann School of Medicine, University of Pennsylvania, and Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology.
Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines.
Dr. Offit is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal.
Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of a landmark rotavirus vaccine recommended for universal use in infants by the CDC.
For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation’s Living Proof Project for global health. In addition, he has received numerous other awards and honors for his groundbreaking work.
Dr. Offit is also an author of many books including, but not limited to: Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases, Overkill: When Modern Medicine Goes Too Far, The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis, Breaking the Antibiotic Habit, Do You Believe in Magic, and his most recent, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation.
Scientists long believed the brain was immutable, unable to recover functions lost to injury or disease. But in the past few decades, researchers have devised methods to manipulate the brain and central nervous system to help the paralyzed move and enable the blind to see, and they’re moving closer to restoring lost cognitive abilities.
“We are at an inflection point where we are starting to give functions back to people,” said Michael Lim, MD, professor and chair of neurosurgery.
Steelmaking is currently extremely carbon intensive, accounting for about 7% of total global greenhouse gas emissions. As we continue to use ever more steel for new infrastructure around the world, the task of decarbonising the industry is growing ever more urgent. Hydrogen can now perform that task and Volvo has just taken delivery of the first consignment of carbon-free steel. So how is it done, and will it be a gamechanger for the auto industry and wider world?
Video Transcripts available at our website.
http://www.justhaveathink.com.
Help support this channels independence at http://www.patreon.com/justhaveathink.
Or with a donation via Paypal by clicking here.
https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=GWR73EHXGJMAE&source=url.
You can also help keep my brain ticking over during the long hours of research and editing via the nice folks at BuyMeACoffee.com.
https://www.buymeacoffee.com/justhaveathink.
Interested in mastering and remembering the concepts that I present in my videos? Check out the FREE Dive Deeper mini-courses offered by the Center for Behavior and Climate. These mini-courses teach the main concepts in select JHAT videos and go beyond to help you learn additional scientific or conservation concepts. The courses are great for teachers to use or for individual learning. https://climatechange.behaviordevelopmentsolutions.com/just-have-a-think-jhat.
I’m convinced a lot of diseases, MS, parkinsons, alzheimers, most cancers, are the result of bacterial or viral infections.
Building on a growing body of evidence linking viral infections with neurodegenerative disease, a new study published in Nature Communications has demonstrated how certain molecules on the surfaces of viruses can promote the aggregation of toxic proteins associated with diseases such as Alzheimer’s and Parkinson’s.
The idea that microbial infections can trigger neurodegenerative disease is not new. As far back as the 1950s scientists have been postulating ways an acute viral infection can lead to progressive neurological problems years, or even decades, later.
While evidence for this association is certainly growing, the mechanisms by which viral threats can influence the progression of brain diseases are still resolutely hypothetical. A common hypothesis speculates some viral infections may trigger abnormal immune responses that subsequently linger for years, ultimately generating neurological damage associated with some brain diseases.
I am pleased to share our most recent video on the “Dementia Safety Study” funded by Maximum Life Foundation and run by IHS, in which BioViva did the data analysis. This treatment shows promise for the millions of people who have dementia today. Though not a cure, it is a step in the right direction.
Can gene therapy delay or reverse Alzheimer’s and other dementias?
Want to learn more about BioViva? Visit: https://bioviva-science.com/
Interested in aging tests? https://bioviva-science.com/collections/products.
Facebook https://www.facebook.com/BiovivaScience.
Twitter https://twitter.com/BioVivaScience.
Instagram https://www.instagram.com/biovivascience.
LinkedIn https://www.linkedin.com/in/liz-parrish.
Summary: Researchers have linked Fragile X and SHANK3 deletion syndrome, two disorders associated with autism, to specific microscopic walking patterns.
Source: Rutgers.
Rutgers researchers have linked the genetic disorders Fragile X and SHANK3 deletion syndrome – both linked to autism and health problems – to walking patterns by examining the microscopic movements of those wearing motion-sensored sneakers.
Taking psilocybin can affect one’s emotional state when listening to music, according to new research presented earlier this month at the 34th ECNP Congress in Lisbon.
Psilocybin, the active psychedelic component of magic mushrooms, has previously shown great promise when used in therapy settings for the treatment of depression. Many of these clinical trials often make use of selected music playlists to support the subjective psychedelic experience felt by the trial participant.
Now, scientists believe that this action of combining psilocybin with music may result in enhanced emotional processing on behalf of the participant, implying that music should be treated as a more active component of psilocybin therapy.
Collaboration, transparency & urgency for rare disease research — mike graglia, managing director & co-founder, syngap research fund — SRF.
Mike Graglia is the Managing Director & Co-Founder of the SynGAP Research Fund (SRF — https://www.syngapresearchfund.org/), an organization that he set up in 2018 with his wife Ashley, after their son was diagnosed with a rare neurological disease caused by an insufficiency in SynGAP protein, which causes the life-changing diagnoses of Epilepsy, Autism, sleep disorder and intellectual disability.
The mission of SRF is to improve the quality of life of SynGAP1 patients through the research and development of treatments, therapies and support systems.
Previously, Mike worked at the Emerson Collective, New America Foundation, the Bill and Melinda Gates Foundation, BCG, the World Bank/IFC and the US Peace Corps/Namibia. During his time in Africa he created a small charity to fund girls’ education.
Mike graduated from Gonzaga University with a BS in mathematics. He then attended the Johns Hopkins School of Advanced International Studies (SAIS) and Columbia Business School.
Protein intake is known to be vital for maintaining brain function in older individuals. Now, using a mouse model of Alzheimer’s disease, researchers have shown that the intake of a specific set of amino acids can inhibit the death of brain cells, protect the connections between them, and reduce inflammation, preserving brain function. Their research suggests that this amino acid combination called Amino LP7 can hinder the development of dementia, including Alzheimer’s disease.
